Stat3 Activation in Breast Cancer
Author Information
Author(s): Berishaj Marjan, Gao Sizhi Paul, Ahmed Simi, Leslie Kenneth, Al-Ahmadie Hikmat, Gerald William L, Bornmann William, Bromberg Jacqueline F
Primary Institution: Memorial Sloan-Kettering Cancer Center
Hypothesis
The IL-6/gp130/Jak pathway is a principal mechanism of Stat3 activation in breast cancer.
Conclusion
Stat3 activation in breast cancer is primarily mediated through the IL-6/gp130/Jak signaling pathway.
Supporting Evidence
- Stat3 is constitutively activated in more than 50% of primary breast tumors.
- High IL-6 levels have been linked to poor prognosis in breast cancer.
- Blocking the IL-6 receptor reduces Stat3 activation in breast cancer cell lines.
- Stat3 activation correlates with IL-6 expression in primary breast tumors.
Takeaway
This study found that a protein called Stat3 is turned on in many breast cancer cases, and it gets activated by a signal from a molecule called IL-6.
Methodology
The study examined breast cancer-derived cell lines and primary breast cancer specimens for levels of tyrosine-phosphorylated Stat3 and IL-6 using immunohistochemistry and other assays.
Limitations
The study did not find a correlation between Stat3 activation and hormone receptor status in breast tumors.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website